A Phase 1, Open-Label, Fixed-Sequence, Drug Interaction Study to Investigate the Effect of Once-Weekly Rifapentine and Isoniazid on the Pharmacokinetics of Steady-State Doravirine
Latest Information Update: 16 May 2022
Price :
$35 *
At a glance
- Drugs Doravirine (Primary) ; Isoniazid (Primary) ; Rifapentine (Primary)
- Indications HIV-1 infections; Tuberculosis
- Focus Pharmacokinetics
- Acronyms DORIIS
- 21 Mar 2020 Results assessing effect of once-weekly Rifapentine and Isoniazid on the pharmacokinetics of Doravirine in healthy volunteers presented at the 121st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
- 11 Sep 2019 Status changed from active, no longer recruiting to completed.
- 08 Jul 2019 Planned End Date changed from 1 Sep 2019 to 1 Aug 2019.